A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
PHASE2
This phase 2b study will evaluate the efficacy and safety of 16 and 24 week...
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
PHASE2
This phase 2b study will evaluate the efficacy and safety of 16 and 24 week...
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
PHASE2
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-...